Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter A. Fasching is active.

Publication


Featured researches published by Peter A. Fasching.


Breast Care | 2006

Follow-Up for Breast Cancer – the Patients’ View

Hans-Joachim Stemmler; Petra Stieber; Dorit Lässig; Ingo Bauerfeind; Peter A. Fasching; Matthias W. Beckmann; Margrit Glattes; Ursula Goldmann-Posch; Verena Hoffmann; Volker Heinemann

International and national guidelines (S3 guideline) for the surveillance of post-treatment breast cancer patients recommend a clinical follow-up including routine history and physical examination and regular mammograms. The practice of a clinical follow-up has been often discussed, but has been proven not to be inferior when compared to an intensified follow-up in randomized trials. Patients and Methods: The present manuscript reports the patients’ view on the basis of a survey including 2000 patients with a history of breast cancer. Results: A total of 452 patients (22.6%) answered the questionnaire. The median age was 62 years (range 23-85 years). More than 80% of the patients were disease- free at the time of the survey. The need for surveillance was affirmed by the majority of patients (>95%), and one third stated that there was a need for more technical efforts during follow-up. In contrast to the follow-up guidelines, the results of the present survey indicated that most of the regularly scheduled follow-up visits were expanded using extensive laboratory and imaging procedures. Conclusion: This survey shows that the majority of physicians obviously do not accept the present follow-up guidelines. A new surveillance study investigating the efficacy of an intensified surveillance based on the improved possibilities of modern diagnostics and endocrine, immunotherapeutic, chemotherapeutic and interventional treatment options is warranted.


Geburtshilfe Und Frauenheilkunde | 2017

Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy

Rüdiger Schulz-Wendtland; Peter Dankerl; Mayada R. Bani; Peter A. Fasching; Katharina Heusinger; Michael P. Lux; Sebastian M. Jud; Claudia Rauh; Christian M. Bayer; Michael G. Schrauder; Matthias W. Beckmann; Michael Uder; Barbara Brehm; Christian R. Loehberg

Introduction The placement of intramammary marker clips has proven to be helpful for tumor localization in patients undergoing neoadjuvant chemotherapy and breast-conserving surgery. The purpose of our study was to investigate the feasibility of using a clip marker system for breast cancer localization and its influence on the imaging assessment of treatment responses after neoadjuvant chemotherapy. Patients and Methods Between March and June 2015, a total of 25 patients (n = 25), with a suspicion of invasive breast cancer with diameters of at least 2 cm (cT2), underwent preoperative sonographically guided core needle biopsy using a single-use breast biopsy system (HistoCore™) and intramammary clip marking using a directly adapted clip system based on the established O-Twist Marker™, before their scheduled preoperative neoadjuvant chemotherapy. Localization of the intramammary marker clip was controlled by sonography and digital breast tomosynthesis. Results Sonography detected no dislocation of intrammammary marker clips in 20 of 25 patients (80 %), while digital breast tomosynthesis showed accurate placement without dislocation in 24 patients (96 %) (p < 0.05). There was no evidence of significant clip migration during preoperative follow-up imaging after neoadjuvant chemotherapy. No complication related to the clip marking was noted and there was no difficulty in evaluating the treatment response to neoadjuvant chemotherapy. Among the breast-conserving surgeries performed, no cases were identified in which intraoperative loss of the marker clip had occurred. Conclusion Our study underscores the importance of intramammary marking clip systems before neoadjuvant chemotherapy. Placement of marker clips is advised to facilitate accurate tumor bed localization. With regard to digital breast tomosynthesis, its development continues to improve the quality of diagnostics and the therapy of breast cancer particularly for small breast cancer tumors or in neoadjuvant chemotherapy setting.


International Workshop on Digital Mammography | 2014

Fully Automated Nipple Detection in 3D Breast Ultrasound Images

Lei Wang; Tobias Böhler; Fabian Zöhrer; Joachim Georgii; Claudia Rauh; Peter A. Fasching; Barbara Brehm; Rüdiger Schulz-Wendtland; Matthias W. Beckmann; Michael Uder; Horst K. Hahn

Nipple position provides useful diagnostic informations in reading automated 3D breast ultrasound (ABUS) images. The identification of nipples is required to localize and determine the quadrants of breast lesions. Additionally, the nipple position serves as an effective landmark to register an ABUS image to other imaging modalities, such as digital mammography, breast magnet resonance imaging (MRI), or tomosynthesis. Nevertheless, the presence of speckle noise induced by interference waves and variant imaging directions in ultrasonography poses challenges to the task. In this work, we propose a fast and automated algorithm to detect nipples in 3D breast ultrasound images. The method fully takes advantages of the consistent characteristics of ultrasonographic signals observed at nipples and employs a multi-scale Laplacian-based blob detector to eventually identify nipple positions. The accuracy of the proposed method was tested on 113 ABUS images, resulting in a distance error of 6.6±8.9 mm (mean ±std).


Archive | 2017

Zukünftige Entwicklungen in der Bildgebung

G. Anton; Pa Baltzer; Julius Emons; Peter A. Fasching; Rüdiger Schulz-Wendtland; Christian Weismann

Die Zukunft technischer Entwicklungen vorhersagen zu wollen ist immer auf einer subjektiven Einschatzung begrundet und daher naturgemas schwierig. Um die Zukunft der Bildgebung abschatzen zu konnen, wird jeweils die aktuelle Situation beleuchtet und davon ausgehend mogliche Entwicklungen dargestellt. Dabei ist ein zentraler Punkt die heute mithilfe von Computersystemen erhobene umfangreiche Menge von Patientendaten, die mit bestehenden Techniken neu verknupft werden.


Archive | 2017

Risikoadaptierte Diagnostik und Therapie

Matthias W. Beckmann; Charlotte Sell; Peter A. Fasching

Das Mammakarzinom ist die haufigste Malignomerkrankung bei Frauen. Fur eine erfolgreiche Diagnostik und Pravention des Mammakarzinoms ist daher eine moglichst genaue Bestimmung des individuellen Erkrankungsrisikos essenziell. In den letzten Jahren wurden neue Erkenntnisse bezuglich einerseits genetischer Risikofaktoren und andererseits auch deren Interaktion mit etablierten klinischen Risikofaktoren gewonnen. Diese Informationen beeinflussen das klinische Management von Brustkrebs zentral und sind Teil des Weges zu einer personalisierten Diagnostik und Therapie.


Archive | 2010

Nachsorge mit Rezidiv- und Metastasensuche und Therapiebegleitung

Matthias W. Beckmann; Laura Kahmann; Peter A. Fasching

Das Mammakarzinom ist die haufigste Krebserkrankung der Frau und insgesamt fur mehr als 27% aller Krebserkrankungsfalle bei Frauen verantwortlich. Insgesamt wird also jede achte Frau im Laufe ihres Lebens diesem schicksalhaften Einschnitt gegenuber stehen, welcher sowohl sie als Individuum als auch ihre Umgebung betrifft.


Archive | 2002

Molekulare Medizin in der Frauenheilkunde

Matthias W. Beckmann; Peter A. Fasching; Peter Dall; Jan-Steffen Krüssel; Dieter Niederacher; B. Tutschek


Senologie - Zeitschrift für Mammadiagnostik und -therapie | 2018

Galaktografie mit Tomosynthese (Galaktomosynthese) – Renaissance einer Methode?

Rüdiger Schulz-Wendtland; Caroline Preuss; Peter A. Fasching; Christian R. Loehberg; Michael P. Lux; Julius Emons; Matthias W. Beckmann; Michael Uder; Markus Mueller-Schimpfle


Senologie - Zeitschrift für Mammadiagnostik und -therapie | 2018

Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs?

A Polasik; Marie Tzschaschel; Fabienne Schochter; Ameli de Gregorio; Thomas W. P. Friedl; Brigitte Rack; Andreas D. Hartkopf; Peter A. Fasching; Andreas Schneeweiss; Volkmar Müller; Jens Huober; Wolfgang Janni; Tanja Fehm


Facharztwissen Gynäkologie (2. Auflage)#R##N#Mit Zugang zur Medizinwelt | 2018

Therapeutische Grundlagen in der gynäkologischen Onkologie

Peter A. Fasching; Diego Hoffmeister; Jens Huober; Christian Löhberg; Peter Steffen; Michael G. Schrauder; Charlotte Sell; Uta Kraus-Tiefenbacher; Frederik Wenz

Collaboration


Dive into the Peter A. Fasching's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rüdiger Schulz-Wendtland

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Michael Uder

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Claudia Rauh

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Julius Emons

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Arndt Hartmann

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Michael G. Schrauder

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Michael P. Lux

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Sebastian M. Jud

University of Erlangen-Nuremberg

View shared research outputs
Top Co-Authors

Avatar

Alexander Hein

German Cancer Research Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge